Endeavor Bio adds $101M to test ex-Eli Lilly, Roche drug in cancer & lung fibrosis

Endeavor Bio adds $101M to test ex-Eli Lilly, Roche drug in cancer & lung fibrosis

Source: 
MedCity News
snippet: 

Endeavor BioMedicines aims to kill two birds with one stone—that stone being a small molecule drug. Taladegib targets a cell signaling pathway associated with both cancer and idiopathic pulmonary fibrosis, and the biotech will apply its Series B round toward clinical tests of the molecule on both fronts.